en.Wedoany.com Reported - On April 2, 2026, the China National Medical Products Administration approved the market launch of Technetium [99mTc] Pexidartide Peptide Injection (99mTc-3PRGD2) and its accompanying kit, developed by China's Foshan Radiomedicine Co., Ltd. This drug is used for the auxiliary diagnosis of regional lymph node metastasis in patients with suspected lung cancer. This is China's first approved independently developed Class 1 innovative nuclear drug, and it is also the world's first broad-spectrum tumor imaging agent for SPECT imaging. It breaks through the international status quo of nuclear medicine tumor diagnosis relying primarily on PET technology for nearly 30 years.
Targeting integrin αvβ3, this drug can precisely bind to receptors on the surface of tumor cells and their neovascular endothelial cells, achieving precise SPECT imaging of tumors. Compared to PET technology, it relies on more widely available SPECT equipment in China and a more economical preparation process, which can reduce diagnosis and treatment costs, improve the accessibility of nuclear medicine in tumor diagnosis, staging, and efficacy monitoring, and meet the precise diagnostic needs of over 4.5 million new cancer patients in China each year. The introduction of this SPECT broad-spectrum tumor imaging agent is expected to optimize the allocation of medical resources.
As China's radiopharmaceutical market is projected to grow to 26 billion yuan by 2030, the nuclear drug industry is entering a rapid development phase. The approval of this drug marks significant progress for China in the field of original nuclear drugs. It may provide a more accessible domestic solution for precise tumor diagnosis and treatment and further promote the application of SPECT broad-spectrum tumor imaging agents.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
